Drug intelligence / Profile preview

AYUB 00

Development stage: Preclinical
Lead developer: AYUB R&D
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules

Overview

AYUB 00 is a preclinical-stage therapeutic candidate developed by AYUB R&D, consisting of an enriched essential oil extract derived from *Boswellia sacra* (frankincense). The drug is specifically being investigated for the treatment of colorectal cancer. While the exact molecular targets are not publicly disclosed, the extract is enriched for bioactive components intended to exert antineoplastic effects, likely through the induction of apoptosis and inhibition of pro-inflammatory signaling pathways within the tumor microenvironment.

Other names: enriched Boswellia sacra essential oil extract

Beyond the preview

Go deeper on AYUB 00.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AYUB 00.

Explore the full profile